Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Gastroenterology
Published in: Current Treatment Options in Gastroenterology 1/2018

01-03-2018 | Inflammatory Bowel Disease (G Lichtenstein, Section Editor)

Management of Anemia in Patients with Inflammatory Bowel Disease (IBD)

Authors: Dhruvan Patel, MD, Chinmay Trivedi, MBBS, Nabeel Khan, MD

Published in: Current Treatment Options in Gastroenterology | Issue 1/2018

Login to get access

Abstract

Purpose of Review

Anemia is the most common complication as well as an extra intestinal manifestation of inflammatory bowel disease (IBD). It is associated with a significant impact on patient’s quality of life (QoL); as well it represents a common cause of frequent hospitalization, delay of hospital inpatient discharge and overall increased healthcare burden. In spite of all these, anemia is still often underdiagnosed and undertreated. Our aim in this review is to provide a pathway for physicians to help them achieve early diagnosis as well as timely and appropriate treatment of anemia which in turn would hopefully reduce the prevalence and subsequent complications of this condition among IBD patients.

Recent Findings

The etiology of anemia among IBD patients is most commonly due to iron deficiency anemia (IDA) followed by anemia of chronic disease. Despite this, more than a third of anemic ulcerative colitis (UC) patients are not tested for IDA and among those tested and diagnosed with IDA, a quarter are not treated with iron replacement therapy. A new algorithm has been validated to predict who will develop moderate to severe anemia at the time of UC diagnosis. While oral iron is effective for the treatment of mild iron deficiency-related anemia, the absorption of iron is influenced by chronic inflammatory states as a consequence of the presence of elevated levels of hepcidin. Also, it is important to recognize that ferritin is elevated in chronic inflammatory states and among patients with active IBD, ferritin levels less than 100 are considered to be diagnostic of iron deficiency. Newer formulations of intra-venous (IV) iron have a good safety profile and can be used for replenishment of iron stores and prevention of iron deficiency in the future.

Summary

Routine screening for anemia is important among patients with IBD. The cornerstone for the accurate management of anemia in IBD patients lies in accurately diagnosing the type of anemia. All IBD patients with IDA should be considered appropriate for therapy with iron supplementation whereas IV administration of iron is recommended in patients with clinically active IBD, or for patients who are previously intolerant to oral iron, with hemoglobin levels below 10 g/dL, and in patients who need erythropoiesis-stimulating agents (ESAs). As the recurrence of anemia is common after resolution, the monitoring for recurrent anemia is equally important during the course of therapy.
Literature
1.
Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006;24:1507–23.PubMedCrossRef
2.
de la Morena F, Gisbert JP. Anemia and inflammatory bowel disease. Rev Esp Enferm Dig. 2008;100:285–93.PubMed
3.
4.
Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1299–307.PubMedCrossRef
5.
Danese S, Hoffman C, Vel S, et al. Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn’s and Ulcerative Colitis Association’s online survey. Eur J Gastroenterol Hepatol. 2014;26:1385–91.PubMed
6.
Stein J, Bager P, Befrits R, et al. Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. Eur J Gastroenterol Hepatol. 2013;25:1456–63.PubMedCrossRef
7.
Blumenstein I, Dignass A, Vollmer S, et al. Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: the German AnaemIBD Study. J Crohns Colitis. 2014;8:1308–14.PubMedCrossRef
8.
Bager P, Befrits R, Wikman O, et al. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scand J Gastroenterol. 2011;46:304–9.PubMedCrossRef
9.
Voegtlin M, Vavricka SR, Schoepfer AM, et al. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J Crohns Colitis. 2010;4:642–8.PubMedCrossRef
10.
Bager P, Befrits R, Wikman O, et al. High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia: a longitudinal 2- year follow-up study. Scand J Gastroenterol. 2013;48:1286–93.PubMedCrossRef
11.
• Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data metaanalysis. Inflamm Bowel Dis. 2014;20:936–45. A recent analysis of the frequency of anaemia in IBD patients in European countries.PubMedCrossRef
12.
Rejler M, Tholstrup J, Andersson-Gare B, et al. Low prevalence of anemia in inflammatory bowel disease: a population-based study in Sweden. Scand J Gastroenterol. 2012;47:937–42.PubMedCrossRef
13.
Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010;95:199–205.PubMedCrossRef
14.
Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev. Gastroenterol Hepatol. 2010;7:599–610.
15.
16.
Pizzi LT, Weston CM, Goldfarb NI, Moretti D, Cobb N, Howell JB, et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(1):47–52.PubMedCrossRef
17.
Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123–30.PubMedCrossRef
18.
Ershler WB, Chen K, Reyes EB, Dubois R. Economic burden of patients with anemia in selected diseases. Value Health. 2005;8:629–38.PubMedCrossRef
19.
Ott C, Liebold A, Takses A, et al. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterol Res Pract. 2012;2012:595970.PubMedPubMedCentralCrossRef
20.
Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846–53. e841–42
21.
22.
23.
Perry GS, Byers T, Yip R, Margen S. Iron nutrition does not account for the hemoglobin differences between blacks and whites. J Nutr. 1992;122:1417–24.PubMedCrossRef
24.
WHO, UNICEF, UNU. Iron deficiency anemia: assessment, prevention and control. Report of a joint WHO/UNICEF/UNU consultation. Geneva: World Health Organization 1998.
25.
Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13(12):1545–53.PubMedCrossRef
26.
Murawska N, Fabisiak A, Fichna J. Anemia of chronic disease and iron deficiency anemia in inflammatory bowel diseases: pathophysiology, diagnosis, and treatment. Inflamm Bowel Dis. 2016;22(5):1198–208.PubMedCrossRef
27.
Mucke V, Mucke MM, Raine T, Bettenworth D. Diagnosis and treatment of anemia in patients with inflammatory bowel disease. Ann Gastroenterol. 2017;30(1):15–22.PubMed
28.
29.
Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMA J. 2008;179:333–7.CrossRef
30.
• Battat R, Kopylov U, Szilagyi A, et al. Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management. Inflamm Bowel Dis. 2014;20:1120–8. This very comprehensive review shows that vitamin B12 deficiency anaemia is not uncommon after restorative proctocolectomy, and that it has negative effects on the patient’s quality of lifePubMed
31.
M’Koma AE, Wise PE, Schwartz DA, et al. Prevalence and outcome of anemia after restorative proctocolectomy: a clinical literature review. Dis Colon Rectum. 2009;52:726–39.PubMedPubMedCentralCrossRef
32.
33.
Bermejo F, Algaba A, Guerra I, et al. Should we monitor vitamin B12 and folate levels in Crohn’s disease patients? Scand J Gastroenterol. 2013;48:1272–7.PubMedCrossRef
34.
35.
De Clerck YA, Ettenger RB, Ortega JA, Pennisi AJ. Macrocytosis and pure RBC anemia caused by azathioprine. Am J Dis Child 1980;134:377–9. European Consensus on the Diagnosis and Management of Iron Deficiency 221.
36.
Formea CM, Myers-Huentelman H, Wu R, et al. Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. Am J Transplant. 2004;4:1810–7.PubMedCrossRef
37.
Agrawal A, Parrott NR, Riad HN, Augustine T. Azathioprine induced pure red cell aplasia: case report and review. Transplant Proc. 2004;36:2689–91.PubMedCrossRef
38.
Old CW, Flannery EP, Grogan TM, Stone WH, San Antonio RP. Azathioprine-induced pure red blood cell aplasia. JAMA. 1978;240:552–4.PubMedCrossRef
39.
Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci. 1983;28(9):833–42.PubMedCrossRef
40.
Gutierrez-Ureña S, Molina JF, García CO, Cuéllar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39(2):272.PubMedCrossRef
41.
Giannadaki E, Potamianos S, Roussomoustakaki M, et al. Autoimmune hemolytic anemia and positive Coombs test associated with ulcerative colitis. Am J Gastroenterol. 1997;92:1872–4.PubMed
42.
Manosa M, Doménech E, Sánchez-Delgado J, Bernal I, García-Planella E, Gassull MA. Autoimmune hemolytic anemia associated with ulcerative colitis. Gastroenterol Hepatol. 2005;28(5):283–4.PubMedCrossRef
43.
Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):44S–9S.PubMedCrossRef
44.
•• Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211–22. This paper highlights the current standards in the diagnosis and management of anaemia in IBD patients and is the result of a European consensus process under the guidance of the European Crohn’s and Colitis Organisation [ECCO]PubMedCrossRef
45.
Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition. 2006;22:1210–3.PubMedCrossRef
46.
Hou JK, et al. Assessment of gaps in care and the development of a care pathway for anemia in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2016;23(1):35–43.CrossRef
47.
Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7:1–33.PubMedCrossRef
48.
Polin V, Coriat R, Perkins G, et al. Iron deficiency: from diagnosis to treatment. Dig Liver Dis. 2013;45(10):803–9.PubMedCrossRef
49.
Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(Suppl 1):S4–8.PubMedCrossRef
50.
Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31–8.PubMedCrossRef
51.
Kulnigg S, Teischinger L, Dejaco C, Waldhor T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol. 2009;104:1460–7.PubMedCrossRef
52.
Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta. 2003;329:9–22.PubMedCrossRef
53.
Oustamanolakis P, Koutroubakis IE, Messaritakis I, et al. Soluble transferrin receptorferritin index in the evaluation of anemia in inflammatory bowel disease: a casecontrol study. Ann Gastroenterol. 2011;24:108–14.PubMedPubMedCentral
54.
Infusino I, Braga F, Dolci A, Panteghini M. Soluble transferrin receptor [sTfR] and sTfR/log ferritin index for the diagnosis of iron-deficiency anemia: a meta-analysis. Am J Clin Pathol. 2012;138:642–9.PubMedCrossRef
55.
Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol. 2011;86:923–7.PubMedCrossRef
56.
Martin J, Radeke HH, Dignass A, Stein J. Current evaluation and management of anemia in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017;11(1):19–32.PubMedCrossRef
57.
Yakut M, Ustun Y, Kabacam G, Soykan I. Serum vitamin B12 and folate status in patients with inflammatory bowel diseases. Eur J Intern Med. 2010;21:320–3.PubMedCrossRef
58.
Alkhouri RH, Hashmi H, Baker RD, Gelfond D, Baker SS. Vitamin and mineral status in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;56:89–92.PubMedCrossRef
59.
Green R. Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies. Am J Clin Nutr. 2011;94:666S–72S.PubMedPubMedCentralCrossRef
60.
Camaschella C. Iron-Deficiency Anemia. N Engl J Med. 2015;373(5):485–6.PubMed
61.
Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–48.PubMedCrossRef
62.
Favrat B, Balck K, Breymann C, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women—PREFER, a randomized, placebo-controlled study. PLoS One. 2014;9:e94217.PubMedPubMedCentralCrossRef
63.
Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. 2011;118:3222–7.PubMedCrossRef
64.
Waldhoer T, Feichtenschlager T, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 2001;96:2382–7.PubMed
65.
Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100:2503–9.PubMedCrossRef
66.
de Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther. 2005;22(11–12):1097–105.PubMedCrossRef
67.
Ruiz-Arguelles GJ, Diaz-Hernandez A, Manzano C, Ruiz-Delgado GJ. Ineffectiveness of oral iron hydroxide polymaltose in iron-deficiency anemia. Hematology. 2007;12(3):255–6.PubMedCrossRef
68.
Kaltwasser JP, Werner E, Niechzial M. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneimittelforschung. 1987;37(1A):122–9.PubMed
69.
Malhotra S, Garg SK, Khullar GK, et al. Kinetics of two different iron formulations and their effect on diurnal variation of serum iron levels. Methods Find Exp Clin Pharmacol. 2004;26(6):417–20.PubMed
70.
Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflammatory Bowel Dis. 2015;21(3):579–88.CrossRef
71.
Schmidt C, Ahmad T, Tulassay Z, et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study. Aliment Pharmacol Ther. 2016;44(3):259–70.PubMedPubMedCentralCrossRef
72.
Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017;4(11):e524–33.PubMedCrossRef
73.
Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and metaanalysis. PLoS One. 2015;10:e0117383.PubMedPubMedCentralCrossRef
74.
Tay HS, Soiza RL. Systematic review and meta-analysis: what is the evidence for oral iron supplementation in treating anaemia in elderly people? Drugs Aging. 2015;32:149–58.PubMedCrossRef
75.
76.
Kara M, Hasinoff BB, DW MK, Campbell NR. Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol. 1991;31(3):257–61.PubMedPubMedCentralCrossRef
77.
Hallberg L, Rossander L, Skånberg AB. Phytates and the inhibitory effect of bran on iron absorption in man. Am J Clin Nut. 1987;45(5):988–96.CrossRef
78.
79.
Kortman GA, Raffatellu M, Swinkels DW, et al. Nutritional iron turned inside out: intestinal stress from a gut microbial perspective. FEMS Microbiol Rev. 2014;38:1202–34.PubMedCrossRef
80.
Okam MM, Koch TA, Tran MH. Iron deficiency anemia treatment response to oral iron therapy: a pooled analysis of five randomized controlled trials. Haematologica. 2016;101:e6–7.PubMedPubMedCentralCrossRef
81.
Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:269–77.PubMedCrossRef
82.
Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose [FERINJECT] randomized controlled trial. Am J Gastroenterol. 2008;103:1182–92.PubMedCrossRef
83.
Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54:306–15.PubMed
84.
Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anemia. Drugs. 2009;69:739–56.PubMedCrossRef
85.
Rodgers GM, Auerbach M, Cella D, Chertow GM, Coyne DW, Glaspy JA, et al. High-molecular weight iron dextran: a wolf in sheep’s clothing? J Am Soc Nephrol. 2008;19(5):833.PubMedCrossRef
86.
Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematol Am Soc Hematol Educ Program. 2010;2010:338.
87.
Yessayan L, Sandhu A, Besarab A, et al. Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy. Int J Nephrol. 2013;2013:703,038.CrossRef
88.
Koutroubakis IE, Oustamanolakis P, Karakoidas C, Mantzaris GJ, Kouroumalis EA. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Dig Dis Sci. 2010;55:2327–31.PubMedCrossRef
89.
Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44:838–45.PubMedCrossRef
90.
Auerbach M, Deloughery T. Single-dose intravenous iron for iron deficiency: a new paradigm. Hematol Am Soc Hematol Educ Program. 2016 Dec;2016(1):57–66.
91.
Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, noninferiority study of intravenous iron isomaltoside 1000 [Monofer] compared with oral iron for treatment of anemia in IBD [PROCEED]. Am J Gastroenterol. 2013;108:1877–88.PubMedPubMedCentralCrossRef
92.
Ford D, Cohen M, Strauss W, et al. Evaluation of ferumoxytol treatment for iron deficiency anemia in patients with gastrointestinal disorders who have a history of unsatisfactory oral iron therapy: results of a Phase III, randomized, placebo-controlled trial. Gastroenterology. 2013;144:S754.CrossRef
93.
Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung. 1992;42:1439–52.PubMed
94.
Aksan A, Işık H, Radeke HH, Dignass A, Stein J. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1303–18. https://​doi.​org/​10.​1111/​apt.​14043.PubMedCrossRef
95.
Dahlerup JF, Jacobsen BA, van der Woude J, Bark LÅ, Thomsen LL, Lindgren S. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 2016;51(11):1332–8.PubMedPubMedCentralCrossRef
96.
Vikrant S, Parashar A. The safety and efficacy of high dose ferric carboxymaltose in patients with chronic kidney disease: a single center study. Indian J Nephrol. 2015;25(4):213.PubMedPubMedCentralCrossRef
97.
Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr. 1970;100:301–3.PubMed
98.
Miller HJ, Hu J, Valentine JK, Gable PS. Efficacy and tolerability of intravenous ferric gluconate in the treatment of iron deficiency anemia in patients without kidney disease. Arch Intern Med. 2007;167(12):1327.PubMedCrossRef
99.
Cavill I, Auerbach M, Bailie GR, et al. Iron and the anemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin. 2006;22:731–7.PubMedCrossRef
100.
Reinisch W, Altorjay I, Zsigmond F, et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol. 2015;50:1226–33.PubMedPubMedCentralCrossRef
101.
Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW. Economic burden of anemia in an insured population. J Manag Care Pharm. 2005;11:565–74.PubMed
102.
103.
104.
Rubin DT, Mulani P, Chao J, et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn’s disease: results from the CHARM trial. Inflamm Bowel Dis. 2012;18:818–25.PubMedCrossRef
105.
Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med. 1997;126:782–7.PubMedCrossRef
106.
Gasche C, Dejaco C, Reinisch W, et al. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion. 1999;60:262–7.PubMedCrossRef
107.
Koutroubakis IE, Karmiris K, Makreas S, Xidakis C, Niniraki M, Kouroumalis EA. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anemia: a pilot study. Eur J Gastroenterol Hepatol. 2006;18:421–5.PubMedCrossRef
108.
Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med. 1996;334:619–23.PubMedCrossRef
109.
110.
Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica. 2008;93(1):90–7.PubMedCrossRef
111.
Hashizume M, Uchiyama Y, Horai N, et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int. 2010;30:917–23.PubMedCrossRef
112.
113.
Leung D, Hill KA, De Rosa DC, et al. LY2928057, an antibody targeting ferroportin, is a potent inhibitor of hepcidin activity and increases iron mobilization in normal cynomolgus monkeys. Blood. 2013;122:3433.
Metadata
Title
Management of Anemia in Patients with Inflammatory Bowel Disease (IBD)
Authors
Dhruvan Patel, MD
Chinmay Trivedi, MBBS
Nabeel Khan, MD
Publication date
01-03-2018
Publisher
Springer US
Published in
Current Treatment Options in Gastroenterology / Issue 1/2018
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-018-0174-2

Other articles of this Issue 1/2018

Current Treatment Options in Gastroenterology 1/2018 Go to the issue

Inflammatory Bowel Disease (G Lichtenstein, Section Editor)

Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease

Esophagus (PG Iyer, Section Editor)

New Developments in the Diagnosis, Therapy, and Monitoring of Eosinophilic Esophagitis

Inflammatory Bowel Disease (G Lichtenstein, Section Editor)

Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017

Esophagus (PG Iyer, Section Editor)

Recent Advances in Screening for Barrett’s Esophagus

Esophagus (PG Iyer, Section Editor)

Emerging Insights into the Esophageal Microbiome

Colon (JC Anderson, Section Editor)

Management of Serrated Polyps of the Colon

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits